TELEFLEX INC

Teleflex’s Q2 beats earnings and revenue, trims outlook, cuts a $1.5 B divestiture, and launches a $250 M buyback—boosting cash and shareholder value while reshaping growth strategy.

Teleflex Q1 2026 earnings beat analysts, projects 4.5‑5.5 % revenue growth, launches a $1 bn share‑buyback and streamlines its portfolio with divestitures.

Teleflex Inc. has declared a quarterly dividend and raised its financial outlook for 2025, citing strong financial performance and a growing demand for medical devices.

Teleflex Inc. reported mixed financial results for Q1 2025, with revenue declining 3.8% but non-GAAP EPS exceeding expectations, amidst regulatory milestones and strategic initiatives.

Teleflex Inc. has received FDA clearance for its QuikClot Control+ device, allowing it to be used for all grades of internal and external bleeding, expanding its application in various medical procedures.